Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 14/20 | 1.00 |
| ▸ | EGFR | P00533 | 14/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | RGS12 | O14924 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw282974X SCHEMBL29556843 | 1.00 | ERBB2 (1.00) | ERBB2EGFRERBB4MEN1RGS12 | |
| Gw282974X SCHEMBL31061539 | 1.00 | ERBB2 (1.00) | ERBB2EGFRERBB4MEN1RGS12 | |
| SCHEMBL6765043 | 0.92 | ERBB2 (0.85) | ERBB2EGFRERBB4MEN1RGS12 | |
| SCHEMBL6768356 | 0.91 | EGFR (0.84) | ERBB2EGFRERBB4MEN1RGS12 | |
| SCHEMBL6767758 | 0.91 | ERBB2 (0.83) | ERBB2EGFRERBB4MEN1RGS12 | |
| SCHEMBL6775170 | 0.91 | EGFR (0.83) | ERBB2EGFRERBB4MEN1RGS12 | |
| Hydrochloric Acid SCHEMBL6767325 | 0.90 | EGFR (0.82) | ERBB2EGFRERBB4MEN1RGS12 | |
| SCHEMBL6767935 | 0.90 | ERBB2 (0.82) | ERBB2EGFRERBB4MEN1RGS12 | |
| Hydrochloric Acid SCHEMBL7015397 | 0.90 | ERBB2 (0.82) | ERBB2EGFRERBB4MEN1RGS12 | |
| Hydrochloric Acid SCHEMBL6774156 | 0.90 | ERBB2 (0.81) | ERBB2EGFRERBB4MEN1RGS12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017183864-A1 | COMPOSITION FOR NOROVIRUS CULTURE AND METHOD FOR NOROVIRUS CULTURE | 전남대학교산학협력단 | 2017-10-26 | — | — | WO | claimed |
| US-9662347-B2 | Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2017-05-30 | — | — | US | claimed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | claimed |
| EP-2400033-B1 | Method for determining sensitivity of tumor cells to tyrosine kinase inhibitor and computer program product | SYSMEX CORP (JP) | 2013-02-20 | — | — | EP | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| US-20110318768-A1 | METHOD FOR DETERMINING SENSITIVITY OF TUMOR CELLS TO TYROSINE KINASE INHIBITOR AND COMPUTER PROGRAM PRODUCT | SYSMEX CORPORATION (JP) | 2011-12-29 | — | — | US | claimed |
| EP-2400033-A1 | Method for determining sensitivity of tumor cells to tyrosine kinase inhibitor and computer program product | SYSMEX CORPORATION (JP) | 2011-12-28 | — | — | EP | claimed |
| US-6723726-B1 | Protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-04-20 | — | — | US | claimed |
| EP-0912570-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2003-09-10 | — | — | EP | claimed |
| US-6174889-B1 | PROTEIN TYROSINE KINASE INHIBITORS RELATED TO BIOISOSTERES OF QUINOLINE AND QUINAZOLINE DERIVATIVES; ANTICARCINOGENIC AND -TUMOR AGENTS; PSORIASIS; RESTENOSIS; RHEUMATOID ARTHRITIS, AUTOIMMUNE DISEASE, ALLERGY, ASTHMA AND GRAFT REJECTION | GLAXO WELLCOME INC. | 2001-01-16 | — | — | US | claimed |
| EP-0912570-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | claimed |
| WO-1998002438-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | claimed |
| US-11406709-B2 | Therapeutic and research application of PDCL3 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-08-09 | — | — | US | disclosed |
| US-9815893-B2 | Anti-VEGF antibodies and their uses | ABBVIE BIOTHERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2894167-B1 | Anti-VEGF Antibodies and their uses | ABBVIE BIOTHERAPEUTICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-6174889-B1 | PROTEIN TYROSINE KINASE INHIBITORS RELATED TO BIOISOSTERES OF QUINOLINE AND QUINAZOLINE DERIVATIVES; ANTICARCINOGENIC AND -TUMOR AGENTS; PSORIASIS; RESTENOSIS; RHEUMATOID ARTHRITIS, AUTOIMMUNE DISEASE, ALLERGY, ASTHMA AND GRAFT REJECTION | GLAXO WELLCOME INC. | 2001-01-16 | — | — | US | disclosed |
| EP-0912570-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998002438-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |